Neoleukin therapeutics, inc. (AQXP)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Revenue (Note 9)

-

25,000

-

-

-

-

-

-

Operating expenses
Research and development (Note 6)

4,417

41,789

36,267

-

-

-

-

-

Acquired in-process research and development (Note 3)

47,716

-

-

-

-

-

-

-

Research and development

-

-

-

28,382

15,799

18,079

7,599

6,045

General and administrative (Note 6)

18,826

15,835

14,852

9,263

5,541

4,296

1,777

1,635

Total operating expenses

70,959

57,624

51,119

37,645

21,340

22,375

9,376

7,681

Loss from operations

-70,959

-32,624

-51,119

-37,645

-

-

-

-

Other income, net
Interest expense and financing costs

-

-

-

-

-

-

43

-

Change in fair value of derivative liabilities (Note 6(a))

-

-

-

-

-

-

962

-

Amortization and extinguishment of remaining discount on preferred shares upon conversion of preferred shares

-

-

-

-

-

1,884

386

45

Interest expense

1

4

4

1

-

451

-

9

Other income, net (Note 11)

1,518

1,043

940

644

-520

683

109

64

Other income, net (Note 7)

1,517

1,039

936

643

-520

-1,652

642

9

Net loss before income taxes

-

-

-

-

-

-

-8,734

-7,671

Income tax recovery (Note 10)

-

-

-

-

-

-

-5

42

Net loss

-69,442

-31,585

-50,183

-37,002

-21,860

-24,027

-8,729

-7,714

Net loss per common stock - basic and diluted (Note 8)

-2.57

-1.34

-2.14

-1.96

-1.73

-2.75

-49.52

-40.23

Basic and diluted weighted average number of common stock outstanding (Note 8)

27,030

23,519

23,450

18,893

12,637

8,667

301

301

Comprehensive loss:
Net loss

-69,442

-31,585

-50,183

-37,002

-21,860

-24,027

-8,729

-7,714

Other comprehensive income—unrealized gain on available-for-sale securities

-

70

99

121

-286

-4

-

-

Comprehensive loss

-69,442

-31,515

-50,084

-36,881

-22,146

-24,031

-8,729

-7,714